BARB
Financiado
Biomedical Applications of Radioactive ion Beams
Cancer remains one of the main causes of death worldwide. In 2018, >50% cancer patients in Europe underwent radiotherapy. While over 80% were treated using high-energy X-rays, the number of patients receiving accelerated protons o...
Cancer remains one of the main causes of death worldwide. In 2018, >50% cancer patients in Europe underwent radiotherapy. While over 80% were treated using high-energy X-rays, the number of patients receiving accelerated protons or heavy ions (charged particle therapy: CPT) is rapidly growing, with nearly 200,000 patients treated up till now. Although CPT offers a better depth-dose distribution compared to common X-ray based techniques, range uncertainty and poor image guidance still limit its application.
Improving accuracy is key to broadening the applicability of CPT. In BARB, we will open a new paradigm in the clinical use of CPT by using high-intensity radioactive ion beams (RIB), produced at GSI/FAIR-phase-0 in Darmstadt, for simultaneous treatment and visualization. This will reduce range uncertainty and extend the applicability of CPT to treatment of small lesions (e.g. metastasis and heart ventricles) with unprecedented precision.
The Facility for Antiprotons and Ion Research (FAIR) is currently under construction at GSI. RIB are one of the main tools for basic nuclear physics studies in the new facility. As part of the ongoing FAIR-phase-0, an intensity upgrade will increase the light ion currents in the existing SIS18 synchrotron. Within this project BARB, we will study four b+ emitters (10,11C, and 14,15O) and build an innovative hybrid detector for online positron emission tomography (PET) and g-ray imaging. This novel detector will acquire both prompt g-rays during the beam-on phase of the pulsed synchrotron beam delivery, and the delayed emission from b+ annihilation during the pulse intervals. The technique will be further validated in vivo by applying it to treatment of small tumors in a mouse model.
BARB will exploit the potential of the Bragg peak in medicine. The project will tweak RIB production in nuclear physics and validate the therapeutic potential of RIB therapy in vivo by empowering simultaneous treatment and visualization.
ver más
Duración del proyecto: 70 meses
Fecha Inicio: 2020-05-04
Fecha Fin: 2026-03-31
Fecha Fin: 2026-03-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-05-04
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-ADG:
ERC Advanced Grant
Cerrada
hace 5 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
GSI HELMHOLTZZENTRUM FUR SCHWERIONENFORSCHUNG...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
375.46K€ |
Participante